Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CHRS
- CUSIP: N/A
- Web: www.coherus.com
Capitalization:- Market Cap: $659.8 million
- Outstanding Shares: 51,346,000
Average Prices:- 50 Day Moving Avg: $13.00
- 200 Day Moving Avg: $17.33
- 52 Week Range: $10.80 - $31.74
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.56
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $165.24 million
- Price / Sales: 3.99
- Book Value: $0.63 per share
- Price / Book: 20.40
Profitability:- EBIDTA: ($111,050,000.00)
- Net Margins: -73.89%
- Return on Equity: -307.41%
- Return on Assets: -63.38%
Debt:- Debt-to-Equity Ratio: 3.27%
- Current Ratio: 4.27%
- Quick Ratio: 4.27%
Misc:- Average Volume: 605,312 shs.
- Beta: 4.32
- Short Ratio: 10.44
Frequently Asked Questions for Coherus BioSciences (NASDAQ:CHRS)
What is Coherus BioSciences' stock symbol?
Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."
How were Coherus BioSciences' earnings last quarter?
Coherus BioSciences, Inc. (NASDAQ:CHRS) released its quarterly earnings results on Monday, August, 7th. The company reported ($1.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.29) by $0.21. The firm earned $1.40 million during the quarter. Coherus BioSciences had a negative net margin of 73.89% and a negative return on equity of 307.41%. View Coherus BioSciences' Earnings History.
When will Coherus BioSciences make its next earnings announcement?
Where is Coherus BioSciences' stock going? Where will Coherus BioSciences' stock price be in 2017?
9 equities research analysts have issued 1-year target prices for Coherus BioSciences' stock. Their predictions range from $20.00 to $46.00. On average, they expect Coherus BioSciences' stock price to reach $34.78 in the next year. View Analyst Ratings for Coherus BioSciences.
What are analysts saying about Coherus BioSciences stock?
Here are some recent quotes from research analysts about Coherus BioSciences stock:
- 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (9/12/2017)
- 2. Maxim Group analysts commented, "The challenge for biosimilar makers of humira is not similar efficacy, it’s winning the IP battle with AbbVie. Coherus, in our view, was ideally positioned to win the biosimilar race as it was founded with a focus on IP." (9/8/2017)
- 3. Credit Suisse Group analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities. Positives from the 4Q16 release that support our thesis: 1) In November of ’16, ACRS reported that two pivotal Phase 3 trials of its lead product candidate A-101 40% Topical Solution met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of seborrheic keratosis (SK) lesions. In February 2017, ACRS submitted a New Drug Application NDA for A-101 40% Topical Solution for the treatment of SK to the FDA. 2) During ’16 ACRS also reported positive data from a Phase 2 trial of A-101 45% Topical Solution for the treatment of common warts. 3) ACRS recently completed a Phase 1 clinical trial of ATI-50001, its investigational JAK inhibitor, for the treatment of alopecia totalis and alopecia universalis. And, 4) ACRS had cash and cash equivalents of $174.1MM as of 12/31/16." (3/16/2017)
Who are some of Coherus BioSciences' key competitors?
Some companies that are related to Coherus BioSciences include Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Athenex (ATNX), Omeros Corporation (OMER), Amarin Corporation PLC (AMRN), Retrophin (RTRX), REGENXBIO (RGNX), ZIOPHARM Oncology (ZIOP), Intra-Cellular Therapies (ITCI) and Vanda Pharmaceuticals (VNDA).
Who are Coherus BioSciences' key executives?
Coherus BioSciences' management team includes the folowing people:
- Dennis M. Lanfear, Chairman of the Board, President, Chief Executive Officer
- Jean-Frederic Viret Ph.D., Chief Financial Officer
- Peter K. Watler, Chief Technology Officer
- Alan C. Herman Ph.D., Chief Scientific Officer
- Barbara K. Finck M.D., Chief Medical Officer
- Mats Wahlstrom, Lead Independent Director
- Christos Richards, Director
- August J. Troendle M.D., Director
- James I. Healy M.D. Ph.D., Independent Director
- V. Bryan Lawlis Jr. Ph.D., Independent Director
Who owns Coherus BioSciences stock?
Coherus BioSciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (4.40%), State Street Corp (2.76%), UBS Asset Management Americas Inc. (2.71%), TIAA CREF Investment Management LLC (1.95%) and Northern Trust Corp (0.90%). Company insiders that own Coherus BioSciences stock include Alan C Herman, Christos Richards, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler. View Institutional Ownership Trends for Coherus BioSciences.
Who sold Coherus BioSciences stock? Who is selling Coherus BioSciences stock?
Coherus BioSciences' stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Teachers Advisors LLC, Candriam Luxembourg S.C.A., Columbus Circle Investors, Kennedy Capital Management Inc., Pacad Investment Ltd., TD Asset Management Inc. and Lord Abbett & CO. LLC. Company insiders that have sold Coherus BioSciences stock in the last year include Alan C Herman, Jean-Frederic Viret and Mats Wahlstrom. View Insider Buying and Selling for Coherus BioSciences.
Who bought Coherus BioSciences stock? Who is buying Coherus BioSciences stock?
Coherus BioSciences' stock was acquired by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., TIAA CREF Investment Management LLC, State of Wisconsin Investment Board, State Street Corp, Macquarie Group Ltd., Northern Trust Corp, Lazard Asset Management LLC and C WorldWide Group Holding A S. View Insider Buying and Selling for Coherus BioSciences.
How do I buy Coherus BioSciences stock?
Shares of Coherus BioSciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Coherus BioSciences' stock price today?
One share of Coherus BioSciences stock can currently be purchased for approximately $12.85.
MarketBeat Community Rating for Coherus BioSciences (NASDAQ CHRS)MarketBeat's community ratings are surveys of what our community members think about Coherus BioSciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Coherus BioSciences (NASDAQ:CHRS)Earnings History by Quarter for Coherus BioSciences (NASDAQ CHRS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | | | | | | N/A |  |
| 8/7/2017 | Q2 2017 | ($1.29) | ($1.08) | | $1.40 million | View | Listen | |
| 5/8/2017 | Q1 2017 | ($1.54) | ($1.54) | | $0.16 million | View | Listen | |
| 3/13/2017 | Q4 2016 | ($1.11) | ($1.71) | $10.00 million | $0.84 million | View | Listen | |
| 11/9/2016 | Q3 2016 | ($1.56) | $1.67 | $7.20 million | $162.80 million | View | Listen | |
| 8/9/2016 | Q2 | ($1.32) | ($1.72) | $6.87 million | $14.07 million | View | Listen | |
| 5/9/2016 | Q1 | ($1.42) | ($1.67) | | $12.36 million | View | Listen | |
| 2/29/2016 | Q4 | ($1.74) | ($1.35) | $8.63 million | $10.20 million | View | Listen | |
| 11/9/2015 | Q3 | | ($1.86) | $16.10 million | $7.20 million | View | Listen | |
| 8/10/2015 | Q215 | | ($1.56) | $488.15 million | $6.87 million | View | Listen | |
| 5/11/2015 | Q115 | | ($1.22) | $488.15 million | $5.81 million | View | Listen | |
| 3/23/2015 | Q414 | ($0.46) | ($1.47) | | $6.50 million | View | Listen | |
| 12/15/2014 | Q212 | | ($1.79) | | $16.10 million | View | N/A | |
| 3/27/2012 | | ($0.02) | ($0.06) | | | View | N/A | |
| 12/1/2011 | | ($0.09) | ($0.08) | | | View | N/A | |
| 9/1/2011 | | $0.01 | ($0.01) | | | View | N/A | |
| 6/2/2011 | | $0.12 | $0.17 | | | View | N/A | |
| 3/24/2011 | | ($0.19) | ($0.08) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Coherus BioSciences (NASDAQ:CHRS)Current Year EPS Consensus Estimate: $-5.13 EPS
Next Year EPS Consensus Estimate: $-2.82 EPS
Dividend History for Coherus BioSciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Coherus BioSciences (NASDAQ:CHRS)Insider Ownership Percentage: 26.28%
Institutional Ownership Percentage: 78.19%
Insider Trades by Quarter for Coherus BioSciences (NASDAQ:CHRS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/8/2017 | Alan C Herman | Insider | Sell | 17,535 | $15.02 | $263,375.70 | |
| 7/5/2017 | Alan C Herman | Insider | Sell | 600 | $15.00 | $9,000.00 | |
| 4/3/2017 | Alan C Herman | Insider | Sell | 11,333 | $20.73 | $234,933.09 | |
| 1/25/2017 | Jean-Frederic Viret | CFO | Sell | 3,900 | $27.00 | $105,300.00 | |
| 12/16/2016 | Jean-Frederic Viret | CFO | Sell | 3,900 | $28.30 | $110,370.00 | |
| 12/8/2016 | Mats Wahlstrom | Director | Sell | 53,583 | $27.52 | $1,474,604.16 | |
| 12/1/2016 | Alan C Herman | Insider | Sell | 11,333 | $27.40 | $310,524.20 | |
| 10/21/2016 | Jean-Frederic Viret | CFO | Sell | 3,900 | $30.62 | $119,418.00 | |
| 10/3/2016 | Alan C Herman | Insider | Sell | 11,333 | $25.69 | $291,144.77 | |
| 9/26/2016 | Jean-Frederic Viret | CFO | Sell | 3,900 | $29.88 | $116,532.00 | |
| 9/21/2016 | Dennis M Lanfear | Insider | Sell | 4,060 | $31.75 | $128,905.00 | |
| 9/16/2016 | Dennis M Lanfear | Insider | Sell | 2,900 | $31.79 | $92,191.00 | |
| 8/8/2016 | Fmr Llc | Insider | Sell | 100,000 | $29.86 | $2,986,000.00 | |
| 8/5/2016 | Fmr Llc | Insider | Sell | 48,600 | $28.48 | $1,384,128.00 | |
| 8/1/2016 | Alan C Herman | Insider | Sell | 11,333 | $25.54 | $289,444.82 | |
| 7/21/2016 | Peter K Watler | Insider | Sell | 3,991 | $26.13 | $104,284.83 | |
| 7/20/2016 | Peter K Watler | Insider | Sell | 73,741 | $25.02 | $1,844,999.82 | |
| 7/11/2016 | Peter K Watler | Insider | Sell | 43,495 | $20.02 | $870,769.90 | |
| 7/1/2016 | Alan C Herman | Insider | Sell | 4,250 | $16.89 | $71,782.50 | |
| 6/1/2016 | Alan C Herman | Insider | Sell | 4,250 | $18.67 | $79,347.50 | |
| 5/17/2016 | Peter K Watler | Insider | Sell | 12,000 | $20.00 | $240,000.00 | |
| 5/2/2016 | Alan C Herman | Insider | Sell | 4,250 | $19.20 | $81,600.00 | |
| 2/5/2016 | Alan C Herman | Insider | Sell | 2,000 | $15.02 | $30,040.00 | |
| 12/1/2015 | Alan C. Herman | insider | Sell | 11,333 | $29.49 | $334,210.17 | |
| 11/13/2015 | Christos Richards | Director | Sell | 15,000 | $27.49 | $412,350.00 | |
| 11/2/2015 | Alan C. Herman | insider | Sell | 18,416 | $28.71 | $528,723.36 | |
| 10/1/2015 | Alan C. Herman | insider | Sell | 4,250 | $18.98 | $80,665.00 | |
| 9/1/2015 | Alan C. Herman | insider | Sell | 11,333 | $27.39 | $310,410.87 | |
| 8/18/2015 | Mats Wahlstrom | Director | Sell | 6,373 | $33.50 | $213,495.50 | |
| 8/17/2015 | Mats Wahlstrom | Director | Sell | 8,028 | $33.91 | $272,229.48 | |
| 8/14/2015 | Mats Wahlstrom | Director | Sell | 116,554 | $34.24 | $3,990,808.96 | |
| 6/15/2015 | August J Troendle | Director | Sell | 250,000 | $26.68 | $6,670,000.00 | |
| 11/12/2014 | Eli & Co Lilly | Insider | Buy | 164,963 | $13.50 | $2,227,000.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Coherus BioSciences (NASDAQ:CHRS)
Latest Headlines for Coherus BioSciences (NASDAQ:CHRS)
| Source: |
|
| Date | Headline |
|---|
 | Coherus BioSciences, Inc. (CHRS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 17 at 12:54 PM |
| Reviewing Coherus BioSciences (CHRS) & Zafgen (ZFGN)
www.americanbankingnews.com - September 14 at 12:24 PM |
| Head to Head Review: Coherus BioSciences (CHRS) and Its Rivals
www.americanbankingnews.com - September 13 at 4:30 PM |
| Zacks Investment Research Downgrades Coherus BioSciences, Inc. (CHRS) to Hold
www.americanbankingnews.com - September 12 at 8:24 PM |
 | 3 Stocks With McDonald's-Like Return Potential
finance.yahoo.com - September 11 at 10:51 PM |
| Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : September 11, 2017
finance.yahoo.com - September 11 at 5:50 PM |
 | Coherus BioSciences Provides Update on '619 IPR Institution Decision - GlobeNewswire (press release)
globenewswire.com - September 8 at 10:35 PM |
| Coherus BioSciences' (CHRS) Outperform Rating Reiterated at Cowen and Company
www.americanbankingnews.com - September 8 at 9:52 PM |
| Coherus BioSciences, Inc. (CHRS) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - September 8 at 8:21 AM |
| Coherus BioSciences Provides Update on ‘619 IPR Institution Decision
finance.yahoo.com - September 7 at 5:19 PM |
| Coherus BioSciences, Inc. (CHRS) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - September 3 at 6:32 PM |
| Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September - GlobeNewswire (press release)
globenewswire.com - September 1 at 10:29 PM |
| Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September
finance.yahoo.com - September 1 at 5:26 PM |
| Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : August 30, 2017
finance.yahoo.com - August 29 at 10:38 PM |
 | Coherus BioSciences (CHRS) Reports Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for ... - StreetInsider.com
www.streetinsider.com - August 28 at 10:08 PM |
| Coherus BioSciences (CHRS) Reports Positive Topline Results for Clinical ...
www.streetinsider.com - August 28 at 5:07 PM |
 | Coherus Announces Results For Pharmacokinetic Bioequivalence Study For CHS-1420
www.rttnews.com - August 28 at 5:07 PM |
 | Coherus BioSciences Announces Positive Topline Results for Clinical ...
www.nasdaq.com - August 28 at 5:07 PM |
| Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira® Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects
finance.yahoo.com - August 28 at 5:07 PM |
| Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : August 23, 2017
finance.yahoo.com - August 23 at 5:35 PM |
| Coherus BioSciences, Inc. (CHRS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 23 at 2:34 PM |
| Coherus BioSciences (CHRS) to Raise Up to $150M in from Temasek in Two Tranches
www.streetinsider.com - August 21 at 5:02 PM |
| Coherus Secures Private Placement from Temasek
finance.yahoo.com - August 21 at 5:02 PM |
| Coherus Bio Jumps on Private Placement
finance.yahoo.com - August 21 at 5:02 PM |
| Coherus BioSciences, Inc. (CHRS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - August 15 at 9:52 PM |
| Coherus BioSciences, Inc. (CHRS) Insider Alan C. Herman Sells 17,535 Shares
www.americanbankingnews.com - August 10 at 8:02 PM |
 | Here's Why Coherus Biosciences Rose as Much as 22.2% Today - Motley Fool
www.fool.com - August 10 at 3:25 AM |
| See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
finance.yahoo.com - August 9 at 10:22 PM |
| Edited Transcript of CHRS earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 10:22 PM |
| Here's Why Coherus Biosciences Rose as Much as 22.2% Today
finance.yahoo.com - August 8 at 4:56 PM |
| Coherus BioSciences, Inc. (CHRS) Releases Quarterly Earnings Results, Beats Estimates By $0.21 EPS
www.americanbankingnews.com - August 8 at 12:28 PM |
| Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results - GlobeNewswire (press release)
globenewswire.com - August 7 at 10:47 PM |
| Coherus BioSciences (CHRS) Files Petition for IPR of Amgen's ... - StreetInsider.com
www.streetinsider.com - August 7 at 10:47 PM |
| Coherus BioSciences Files Petition for Inter Partes Review of ENBREL® Patent 8,163,522
finance.yahoo.com - August 7 at 5:37 PM |
| Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results
finance.yahoo.com - August 7 at 5:37 PM |
| Coherus BioSciences reports 2Q loss
finance.yahoo.com - August 7 at 5:37 PM |
| Coherus BioSciences, Inc. (NASDAQ:CHRS) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - August 5 at 11:18 PM |
| Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 29 at 12:52 PM |
 | AbbVie to remain cautious on drug pricing, shares fall - Reuters
www.reuters.com - July 28 at 6:49 PM |
| Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th - GlobeNewswire (press release)
globenewswire.com - July 24 at 4:47 PM |
| Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th - Nasdaq
www.nasdaq.com - July 24 at 11:38 AM |
| Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th
finance.yahoo.com - July 24 at 11:38 AM |
| Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 4 at 1:08 PM |
| Coherus BioSciences, Inc. (NASDAQ:CHRS) Expected to Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - July 3 at 2:28 PM |
| Coherus BioSciences (CHRS) Reduces Workforce by 51 Employees - StreetInsider.com
www.streetinsider.com - June 28 at 2:34 AM |
| Coherus BioSciences (CHRS) Reduces Workforce by 51 Employees
www.streetinsider.com - June 27 at 9:32 PM |
| Coherus BioSciences (CHRS) Reports Alternative Fill-Finish Vendor
www.streetinsider.com - June 27 at 4:31 PM |
| Coherus BioSciences (CHRS) Reports Alternative Fill-Finish Vendor - StreetInsider.com
www.streetinsider.com - June 26 at 5:00 PM |
| Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
finance.yahoo.com - June 21 at 3:13 AM |
| Coherus BioSciences, Inc. (CHRS) Earns Outperform Rating from Credit Suisse Group
www.americanbankingnews.com - June 14 at 5:20 PM |
Coherus BioSciences (CHRS) Chart for Friday, September, 22, 2017
